NASDAQ:RTTR

Ritter Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$1.75
-0.01 (-0.57 %)
(As of 07/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.71
▼
$1.78
50-Day Range
$0.45
▼
$4.09
52-Week Range
$0.15
▼
$1.27
Volume122,103 shs
Average Volume14.23 million shs
Market Capitalization$80.77 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.43

Receive RTTR News and Ratings via Email

Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Ritter Pharmaceuticals logo

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Headlines

Docbot Closes Series A Financing Led by Khosla Ventures and Appoints Andrew J. Ritter as CEO
Docbot Closes Series A Financing Led by Khosla Ventures and Appoints Andrew J. Ritter as CEO
May 24, 2021 |  au.finance.yahoo.com
Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19
Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19
June 10, 2020 |  finance.yahoo.com
Qualigen Therapeutics Receives U.S. Patent Notice of Allowance for its STARS™ Technology
Qualigen Therapeutics Receives U.S. Patent Notice of Allowance for its STARS™ Technology
June 4, 2020 |  finance.yahoo.com
Ritter to complete Qualigen tie-up today
Ritter to complete Qualigen tie-up today
May 22, 2020 |  seekingalpha.com
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.
May 22, 2020 |  finance.yahoo.com
Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.
Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.
May 19, 2020 |  finance.yahoo.com
Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting
Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting
May 14, 2020 |  finance.yahoo.com
Ritter Pharmaceuticals Regains Compliance with Nasdaqs Stockholders Equity Requirement for Continued Listing
Ritter Pharmaceuticals Regains Compliance with Nasdaq's Stockholders' Equity Requirement for Continued Listing
May 11, 2020 |  www.benzinga.com
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing
May 11, 2020 |  finance.yahoo.com
RTTR Ritter Pharmaceuticals, Inc. Common Stock
RTTR Ritter Pharmaceuticals, Inc. Common Stock
May 7, 2020 |  www.nasdaq.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.54 out of 5 stars

Medical Sector

3159th out of 4,434 stocks

Pharmaceutical Preparations Industry

1377th out of 1,734 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions

What stocks does MarketBeat like better than Ritter Pharmaceuticals?

Wall Street analysts have given Ritter Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ritter Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) issued its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01.
View Ritter Pharmaceuticals' earnings history.

When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?

Shares of Ritter Pharmaceuticals reverse split on the morning of Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the following people:
  • Mr. Ira Eliot Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 70)
  • Mr. Andrew J. Ritter, Co-Founder, CEO, Pres, Corp. Sec. & Director (Age 36)
  • Mr. Michael D. Step, Consultant & Director (Age 59)
  • Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 59)
  • Ms. Ellen F. Mochizuki, Consultant (Age 52)

Who are some of Ritter Pharmaceuticals' key competitors?

Some companies that are related to Ritter Pharmaceuticals include UroGen Pharma (URGN), Aerovate Therapeutics (AVTE), Aeglea BioTherapeutics (AGLE), DURECT (DRRX), Puma Biotechnology (PBYI), Flexion Therapeutics (FLXN), RedHill Biopharma (RDHL), Celularity (CELU), GX Acquisition (GXGX), MedAvail (MDVL), Millendo Therapeutics (MLND), Verrica Pharmaceuticals (VRCA), Fortress Biotech (FBIO), Taiwan Liposome (TLC) and Clearside Biomedical (CLSD).
View all of RTTR's competitors.

What other stocks do shareholders of Ritter Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), (APA), The Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and (PRMW).

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

What is Ritter Pharmaceuticals' stock price today?

One share of RTTR stock can currently be purchased for approximately $1.75.

How much money does Ritter Pharmaceuticals make?

Ritter Pharmaceuticals has a market capitalization of $80.77 million.

How many employees does Ritter Pharmaceuticals have?

Ritter Pharmaceuticals employs 7 workers across the globe.

What is Ritter Pharmaceuticals' official website?

The official website for Ritter Pharmaceuticals is www.ritterpharmaceuticals.com.

Where are Ritter Pharmaceuticals' headquarters?

Ritter Pharmaceuticals is headquartered at 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067.

How can I contact Ritter Pharmaceuticals?

Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.